Opioid Growth Factor
OGF levels are measurably lower in MS patients compared to non-MS patients, and LDN restored those levels. LDN's intermittent blockade of the OGF receptor leads to increased endogenous OGF production, which inhibits abnormal cell prolifera…
1 sources - 4 claims
OGF levels are measurably lower in MS patients compared to non-MS patients, and LDN restored those levels. LDN's intermittent blockade of the OGF receptor leads to increased endogenous OGF production, which inhibits abnormal cell proliferation and promotes gut mucosal healing. The OGF pathway is the only opioid receptor system involved in regulating cancer cell proliferation. High-dose naltrexone can paradoxically stimulate tumor growth, while low-dose intermittently inhibits OGF-receptor interaction to suppress abnormal cell replication.